US Edition
Hikma delivers a solid H1 performance and re-affirms expectations for strong growth in the second half - QUICK NEWS AFRICA
Summary by QUICK NEWS AFRICA
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Hikma delivers a solid H1 performance and re-affirms expectations for strong growth in the second half - QUICK NEWS AFRICA
Hikma Pharmaceuticals PLC and its subsidiaries (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its interim results for the six months ended 30 June 2025. The Group reported revenue growth of 6% (5% in constant currency) to $1.658 billion (compared to $1.569 billion in H1 2024). We continued to implement our strategic priorities in
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium